Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that lowers blood glucose by promoting its excretion in the urine. It also offers cardiovascular and renal protection, making it a preferred agent in patients with type 2 diabetes and coexisting heart or kidney conditions.